EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Response to alemtuzumab-based therapy and long-term survival after allogeneic transplantation in T-Cell prolymphocytic leukemia: a systematic review and meta-analysis of proportions

Jamiel Reyes, Alexander Reyes

European Journal of Clinical Pharmacology · 2026

DOI: 10.1007/s00228-026-04182-9 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Clinical Pharmacology, 2026. Verfasst von Jamiel Reyes und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Universidad de Ciencias Médicas de Holguín, Holguín, Cuba. jamielluisreyes@gmail.com. Hauptthemen laut MEDLINE: Alemtuzumab, Leukemia, Prolymphocytic, T-Cell, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Immunological. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive neoplasm with poor outcomes. Alemtuzumab and allogeneic hematopoietic cell transplantation (allo-HCT) are the mainstays of treatment, yet estimates rest on small single-arm studies, and no synthesis has pooled both outcomes. We quantified response to alemtuzumab-based therapy and long-term survival after allo-HCT.

Methods

We performed a systematic review and meta-analysis of proportions. MEDLINE, CENTRAL, ClinicalTrials.gov, Google Scholar, were searched from inception to June 2026. Studies reporting response to alemtuzumab-based therapy or survival after allo-HCT in adults with T-PLL were eligible. Sensitivity analyses assessed robustness, while publication bias (Egger's test), risk of bias (JBI), and certainty (GRADE) were assessed.

Results

Seven studies (200 patients) informed the primary analysis. The pooled overall response rate was 81.9% (95% CI 66.6–91.1; I²=78%) and complete response rate 58.5% (95% CI 39.6–75.2; I²=76%); heterogeneity was explained by line of therapy (frontline 85%, relapsed/refractory 51%; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlemtuzumabLeukemia, Prolymphocytic, T-CellHematopoietic Stem Cell TransplantationAntineoplastic Agents, ImmunologicalHumansTransplantation, HomologousTreatment Outcome

Stichwörter der Autor:innen

T-cell prolymphocytic leukemiaalemtuzumaballogeneic hematopoietic cell transplantationcomplete responsemeta-analysis of proportionsoverall response rateoverall survivalsystematic review

Substanzen

AlemtuzumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Internal Medicine, Universidad de Ciencias Médicas de Holguín, Holguín, Cuba. jamielluisreyes@gmail.com.
  • , Houston, TX, USA. jamielluisreyes@gmail.com.
  • Department of Software Engineering, Universidad de Holguín, Holguín, Cuba.

Zitieren

APA

Reyes, J., & Reyes, A. (2026). Response to alemtuzumab-based therapy and long-term survival after allogeneic transplantation in T-Cell prolymphocytic leukemia: a systematic review and meta-analysis of proportions. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-026-04182-9

Vancouver

Reyes J, Reyes A. Response to alemtuzumab-based therapy and long-term survival after allogeneic transplantation in T-Cell prolymphocytic leukemia: a systematic review and meta-analysis of proportions. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-026-04182-9

BibTeX
@article{Reyes2026,
  author = {Reyes, Jamiel and Reyes, Alexander},
  title = {Response to alemtuzumab-based therapy and long-term survival after allogeneic transplantation in T-Cell prolymphocytic leukemia: a systematic review and meta-analysis of proportions},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1007/s00228-026-04182-9}
}
Kostenlos starten →